These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-003841-14 A pilot evaluation of the pharmacokinetic and safety characteristics of TMC114/ritonavir and TMC125 co-administered to HIV-1-infected subjects with limited treatment options not-yet-due
Ongoing 2005-004430-41 Effect of food on the pharmacokinetic profile of saquinavir at steady state in HIV-infected patients treated with saquinavir/ritonavir 1000/100 mg b.i.d. not-yet-due
Ongoing 2006-005609-76 EFFECT OF DIFFERENT MEALS ON THE PHARMACOKINETIC PROFILE OF SAQUINAVIR AT STEADY STATE IN HIV-INFECTED PATIENTS TREATED WITH SAQUINAVIR/RITONAVIR 1000/100 mg BID. not-yet-due
Ongoing 2006-006174-19 A randomised, open label, phase IV comparative study to determine the effects on renal function of continuing treatment with tenofovir versus replacement with abacavir in HIV positive persons not-yet-due
Ongoing 2007-000932-19 A phase IV study to assess the feasibility of substituting double ritonavir-boosted protease inhibitors (PI) with ritonavir-boosted darunavir (DRV/r) in HIV-infected individuals with viral suppression... not-yet-due
Not reported Terminated 2008-000604-88 A phase IV, two-arm, open-label, single-centre randomised pilot study to assess the feasibility of immeidate or deferred switching of HIV-infected individuals intolerant of efavirenz, ritonavir-booste... 2010-07-12 due-trials
Not reported 2008-000674-20 A phase III, double blind, multi centre, randomised placebo controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing Central Nervous System (CNS) ... 2009-07-15 due-trials
Ongoing 2008-006769-95 A Randomised, Placebo Controlled, Phase IV, Safety and Exploratory Immunogenicity Study into the Impact of Maraviroc, an Orally Administered CCR5 Inhibitor, on the Intensification of Immune Function i... not-yet-due
Ongoing 2010-018878-21 A phase III, open-label, single centre, single-arm, pilot study to assess the feasibility of switching, individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity, to ralteg... not-yet-due
Not reported 2011-001913-14 A randomized crossover study of the effects of zinc sulphate supplementation on atazanavir/ritonavir-associated hyperbilirubinemia 2012-03-14 due-trials
Ongoing, reported early 2012-000649-11 A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir – The CINAMMON Study SS... not-yet-due
Reported results 2012-002205-22 A phase III, open-label, multi centre pilot study to assess the feasibility of switching, individuals receiving Atripla or Kivexa plus Efavarinz with continuing Central Nervous System (CNS) toxicity, ... 2013-11-11 due-trials
Ongoing, reported early 2012-002663-10 A phase IV, open-label single-arm study investigating the pharmacokinetics and pharmacodynamics of the antiretroviral combination of rilpivirine and ritonavir-boosted darunavir in therapy-naive HIV-1 ... not-yet-due
Reported results 2012-005525-75 An open label, randomised, pilot trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genotype ... 2016-02-18 due-trials
Listed as ongoing, but also has a completion date 2013-003704-39 An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppress... 2017-12-04 bad-data
Reported results 2014-002284-15 SSAT058: A phase IV, open-label, multi centre pilot study to assess changes in cerebral function parameters in patients without perceived Central Nervous System (CNS) symptoms when switched from tenof... 2017-02-10 due-trials